These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11606834)

  • 1. Evidence-based recommendations for the use of WBC-reduced cellular blood components.
    Ratko TA; Cummings JP; Oberman HA; Crookston KP; DeChristopher PJ; Eastlund DT; Godwin JE; Sacher RA; Yawn DH; Matuszewski KA;
    Transfusion; 2001 Oct; 41(10):1310-9. PubMed ID: 11606834
    [No Abstract]   [Full Text] [Related]  

  • 2. Universal WBC reduction.
    Nightingale SD;
    Transfusion; 2001 Oct; 41(10):1306-9. PubMed ID: 11606833
    [No Abstract]   [Full Text] [Related]  

  • 3. Universal leucocyte-depletion of blood components: cell concentrates and plasma.
    Engelfriet CP; Reesink HW; Pietersz RN; Schwartz DW; Mayr WR; Blajchman MA; Goldman M; Décary F; Sher G; Georgsen J; Sprogøe-Jakobsen U; Kekomäki R; Kühnl P; Seitz R; Maniatis A; Pintér J; Baróti K; Shinar E; Rebulla P; Greppi N; Sirchia G; Faber JC; Flanagan P; Brand A; Lêtowska M; Nel T; Argelagues E; Martin-Vega C; AuBuchon JP; Williamson L; Wallington T
    Vox Sang; 2001 Jul; 81(1):56-77. PubMed ID: 11520421
    [No Abstract]   [Full Text] [Related]  

  • 4. Universal leukoreduction of cellular blood components in 2001?
    Garcia A; Veillon DM; McCaskill D
    Am J Clin Pathol; 2001 Nov; 116(5):778-80. PubMed ID: 11710697
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of leucocyte depletion on the generation and removal of microvesicles and prion related protein in blood components.
    Krailadsiri P; Perry R; Drummond O; Smith K; Hockley D; Seghatchian J; Spring F; Macgregor I; Williamson L; Prowse C; Lubenko A; Anstee D; Barrowcliffe T; Turner M
    Transfus Apher Sci; 2001 Dec; 25(3):177-8. PubMed ID: 11846133
    [No Abstract]   [Full Text] [Related]  

  • 6. A prospective, randomized clinical trial of universal WBC reduction.
    Dzik WH; Anderson JK; O'Neill EM; Assmann SF; Kalish LA; Stowell CP
    Transfusion; 2002 Sep; 42(9):1114-22. PubMed ID: 12430666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.
    Corash L
    Transfus Apher Sci; 2001 Dec; 25(3):179-81. PubMed ID: 11846134
    [No Abstract]   [Full Text] [Related]  

  • 8. Advancing risk assessment for emerging infectious diseases for blood and blood products: proceedings of a public workshop.
    Gallagher LM; Ganz PR; Yang H; Kessler DA; O'Brien SF; Custer BS; Busch MP; Dodd RY; Stramer SL; Walderhaug MO; Forshee RA; Williams AE; Epstein JS; Anderson SA
    Transfusion; 2013 Feb; 53(2):455-63. PubMed ID: 22845334
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation approaches selective/universal leucodepletion: the need for standardised validation strategies.
    Seghatchian MJ; Krailadsiri P
    Transfus Sci; 1998 Dec; 19(4):363-5. PubMed ID: 10351157
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of blood products in shock.
    Nacht A
    Crit Care Clin; 1992 Apr; 8(2):255-91. PubMed ID: 1568140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing recalls and withdrawals of blood components.
    Ramsey G
    Transfus Med Rev; 2004 Jan; 18(1):36-45. PubMed ID: 14689376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood component recalls and market withdrawals: frequency, reasons, and management in the United States.
    Ramsey G
    Transfus Med Rev; 2013 Apr; 27(2):82-90. PubMed ID: 23375736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AABB contributions to plasma safety.
    Triulzi DJ
    Transfusion; 2012 May; 52 Suppl 1():5S-8S. PubMed ID: 22578373
    [No Abstract]   [Full Text] [Related]  

  • 14. The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products.
    O'Mahony B; Turner A
    Vox Sang; 2012 Feb; 102(2):140-3. PubMed ID: 21806632
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components.
    Murphy MF
    Transfus Sci; 1998 Dec; 19(4):343-6. PubMed ID: 10351149
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components.
    Dzieczkowski JS; Barrett BB; Nester D; Campbell M; Cook J; Sugrue M; Andersen JW; Anderson KC
    Transfusion; 1995 Jan; 35(1):20-5. PubMed ID: 7998063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient blood management: an update of current guidance in clinical practice.
    Peters J; Pendry K
    Br J Hosp Med (Lond); 2017 Feb; 78(2):88-95. PubMed ID: 28165794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The computer or electronic crossmatch.
    Butch SH; Oberman HA
    Transfus Med Rev; 1997 Oct; 11(4):256-64. PubMed ID: 9345707
    [No Abstract]   [Full Text] [Related]  

  • 19. How we manage AB plasma inventory in the blood center and transfusion service.
    Yazer M; Eder AF; Land KJ
    Transfusion; 2013 Aug; 53(8):1627-33. PubMed ID: 23614505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucocyte depletion of blood components.
    Bird A
    S Afr Med J; 2001 Oct; 91(10):822-3. PubMed ID: 11732450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.